Gutian Xiao

Professor of Immunology and Immune Therapeutics

Culture and Engagement Director

Is this your profile? Click to edit

Research Funding

Mechanistic difference of NF-kappaB in lung physiology and tumorigenesis
NIH · R01CA258614 · Aug 24, 2022 – Jul 31, 2027 · Role: Co-Principal Investigator
Structural and molecular dissection of NF-kappaB regulation by the ubiquitin E3 ligase PDLIM2 in lung innate immunity and diseases
NIH · R01GM144890 · Mar 10, 2022 – Feb 28, 2026 · Role: Co-Principal Investigator
Faithful mouse modeling of human lung cancer
NIH · R21CA259706 · Apr 1, 2021 – Mar 31, 2023 · Role: Principal Investigator
PDLIM2 as a cancer and chemosensitizing target
NIH · R01CA172090 · Jul 1, 2013 – Apr 30, 2019 · Role: Principal Investigator
Modeling ETP-ALL in mouse
NIH · R21CA175252 · May 1, 2013 – Apr 30, 2016 · Role: Principal Investigator
HTLV deregulation of NF-kappaB2 p100 processing in tumor
NIH · R01CA116616 · Jul 1, 2006 – May 31, 2012 · Role: Principal Investigator

PDLIM2 in lung adenocarcinoma metastasis. Neoplasia. 2026 Sep 25; 81:101371.. View in PubMed
Exploring PDLIM2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma. Br J Cancer. 2026 Aug 08.. View in PubMed
An Advanced Single-Cell RNA Sequencing (scRNA-seq) Protocol Utilizing Custom-Designed Multiplexing. Bio Protoc. 2026 May 05; 16(9):e5678.. View in PubMed
Enhanced HIF-1α cooperation by a human RORγt mutant potentiates Th17 pathogenicity. Cell Rep. 2026 Mar 17; 45(4):117123.. View in PubMed
PDLIM2 repression: a common mechanism in viral lung infection. Immunohorizons. 2026 Mar 10; 10(3).. View in PubMed
Alveolar epithelial NF-κB/RelA guards the lung against bacterial infection. J Immunol. 2026 Feb 09; 215(2).. View in PubMed
PDLIM2 in Lung Adenocarcinoma Metastasis. bioRxiv. 2025 Dec 07.. View in PubMed
Myeloid PDLIM2 repression as a common mechanism of infection susceptibility in lung diseases. Front Immunol. 2025; 16:1669117.. View in PubMed
PDLIM2 Repression: A Common Mechanism in Viral Lung Infection. bioRxiv. 2025 Sep 17.. View in PubMed
NanoPDLIM2-Based Combination Therapy for Lung Cancer Treatment in Mouse Preclinical Studies. Bio Protoc. 2025 Sep 05; 15(17):e5437.. View in PubMed